PTGS2 and Alzheimer disease: A non-selective COX-2 inhibitor (naproxen) reduced the incidence of AD when it was given to patients before the phase of subjective cognitive impairment, but it failed to benefit clinically diagnosed patients [33], reinforcing the notion that the presymptomatic stage of AD offers therapeutic opportunities [3, 4].